News

Amarantus BioScience has released preliminary data from a blood test for multiple sclerosis (MS) called the MSPrecise diagnostic. The company believes that the test could lead to more accurate diagnoses of MS early in the disease’s progression. MSPrecise is a DNA sequencing test designed to identify specific DNA mutations that are associated with the…

In a recent publication in Nature, titled “Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo” a team of researchers from Case Western University and Northwestern University screened a library of small molecules to assess their ability to drive the conversion of…

Multiple sclerosis (MS) presents many life-altering challenges, but most patients naturally focus most often on the physical challenges associated with the condition: problems with movement, sensation and vision that occur as part of disease progression. Unfortunately, depression and suicidal thoughts are common as well. New research suggests that there could be a relationship…

Frost & Sullivan recently published a report entitled “A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market” providing insight into the global multiple sclerosis (MS) drug market. In this report, a competitive evaluation of MS pharmaceutical drugs currently available in the market and experimental drugs in…

Just like any student, Stephanie Butler was excited to start working, in her case as a nurse, when she began experiencing numbness in her limbs and lost sensation below the waist. It was the first time the student nurse was going to administer anesthesia to a patient, three years ago, when after a…

MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of their ongoing clinical study evaluating ibudilast (MN-166) for the treatment of progressive…

US-based Multiple Sclerosis Outcome Assessments Consortium (MSOAC) has invited New Zealand-based Innate Immunotherapeutics Limited to join their efforts to develop clinical outcome assessment tools to be used in clinical research on multiple sclerosis (MS). The tool being developed is expected to include a series of tests while improving, accelerating and evaluating…

The Myelin Repair Foundation (MRF) and National Institutes of Health (NIH) will initiate a clinical trial of guanabenz in people with multiple sclerosis (MS). Guanabenz is FDA-approved for high blood pressure, but it may also prevent myelin loss. The drug could be the first for MS to protect myelin from…

The U.S. Food and Drug Administration (FDA) has announced it will consider marketing approval of ZINBRYTA (daclizumab high-yield process), a potential treatment for relapsing forms of multiple sclerosis (MS). Biogen and AbbVie, who are jointly developing the therapy, have filed a Biologics License Application…

The Multiple Sclerosis Association of America (MSAA) recently published the latest MS Research Update both printed and online at mymsaa.org. This update is a comprehensive overview of research findings on FDA-approved disease-modifying therapies, as well as many experimental treatments for relapsing forms of…

A study published in the journal Multiple Sclerosis and Related Disorders, led by researchers at Mount Sinai in New York and Celgene Cellular Therapeutics revealed that an infusion based on cells derived from the placenta proved to be safe for patients with multiple sclerosis (MS) and a…

After the Phase 2b clinical trial named Abili-T achieved full enrollment with 190 secondary progress multiple sclerosis (SPMS) patients, The Woodlands, Texas-based Opexa Therapeutics is patiently awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016.

In a recent study entitled “Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy,” researchers unraveled a key role for the cytokine GM-CSF in multiple sclerosis progression, suggesting GM-CSF as a target of IFN-β therapy. The study was published in…

Genzyme presented new magnetic resonance imaging (MRI) data from the Lemtrada® (alemtuzumab) clinical development program on April 23, 2015, at the 67th American Academy of Neurology (AAN) Annual Meeting. The company showed that in the extension phase of two Phase III trials (years 3 and 4), the drug continued to protect the nervous…

Researchers at Oregon Health & Science University (OHSU) College of Pharmacy and Oregon State University (OSU) at Corvallis, and Veterans Affairs Medical Center in Portland, Oregon, have documented an “alarming rise” over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis…

The MS Society recently announced it will invest £2 million into the Edinburgh Centre for MS Research. This funding will support the research work of a team of about fifteen world-leading research experts from the University of Edinburgh. The team co-directed by Professors Siddharthan Chandran and Charles ffrench-Constant will continue their…

Tisch MS Research Center of New York (Tisch MSRCNY) researchers presented preliminary results from an FDA-approved Phase I trial, a small-scale investigation in humans using autologous neural stem cells for the treatment of multiple sclerosis (MS). MS is an autoimmune disorder in which the body’s immune system launches an…

Gladstone Institutes scientists have discovered a successful new treatment that could potentially be used in multiple sclerosis (MS). The treatment involves suppressing a protein that traditionally is associated with overall good health. The study, SIRT1 Deacetylates RORγt and Enhances Th17 Cell Generation, appeared April 27, 2015 in the Journal…

MS Views and News (MSVN), a non-profit organization focused on collecting and distributing information about multiple sclerosis (MS), is hosting a series of educational patient programs and events during the month of May. The events have different themes, but are all focused on the management of MS, including medication, avoiding…

The 67th American Academy of Neurology Annual Meeting took place last week in Washington, DC and included eight investigators from the Tisch MS Research Center of New York, whose research efforts focus on finding a cure for multiple sclerosis (MS). The researchers attended the meeting to share data and insights on…

Bayer HealthCare recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT for the treatment of relapsing-remitting multiple sclerosis (MS). BETACONNECT is a new drug delivery option for patients under Bayer’s BETASERON® (interferon beta-1b) therapy. MS is a…

A new study presented last week during the American Academy of Neurology’s 67th Annual Meeting in Washington, DC provides new treatment strategies for multiple sclerosis (MS) using a monoclonal antibody already used in some MS patients. MS is a disease characterized by the destruction of insulating covers on nerve cells…

Actelion Pharma recently announced that it will accelerate the launch of clinical trials involving its lead drug candidate ponesimod, an oral, selective sphingosine-1-phosphate (S1P1). This decision came after a group of scientists working on different phases of clinical trials for the therapy observed mostly positive effects of ponesimod in terms of efficacy, efficiency…

A team led by researchers at the New York University (NYU) Langone Medical Center recently assessed what happens when clinically stable patients with multiple sclerosis (MS) stop taking their medication and found that almost 40% of them experience to some extent a return in disease activity and related symptoms. The…

MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective for treatment of progressive multiple sclerosis, according to results from a recent Phase III trial. MD1003 may have two beneficial effects: 1) increasing myelin, the fatty nerve-insulating…

San Diego based medical software developer CorTechs Labs announced that it has entered into a partnership agreement with multinational pharmaceutical maker Novartis Pharma AG. The two companies will collaborate in further development of Cortechs’ powerful NeuroQuant breakthrough 510(k) cleared software brain volume quantification device that targets identification, measurement and tracking…

The non-profit organization MS Views and News (MSVN) has invited two health care experts on multiple sclerosis (MS) to join their new medical advisory board. Brian Steingo, MD and Patricia Pagnotta, MSN, ARNP-C will co-chair the new board to assist the organization with its mission of offering the…

Biogen has recently announced novel results to support the effectiveness of TECFIDERA (dimethyl fumarate) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results revealed that TECFIDERA significantly reduced disability progression and relapses in RRMS patients who received their diagnosis for the first time and had a highly active form of the disease. TECFIDERA…

Two already available medications could be used to treat multiple sclerosis (MS). In a new study titled, “Drug Based Modulation of Endogenous Stem Cells,” published in the journal Nature on April 20, 2015, scientists report that two drugs could activate stem cells in the brain, possibly repairing MS-induced damage to…

Throughout the years, Dr. Sarah Thomas and Dr. Peter Thomas at Bournemouth University have been developing a program to aid multiple sclerosis patients affected by fatigue. Their program, developed at the Bournemouth University Clinical Research Unit in collaboration with colleagues at Dorset Multiple Sclerosis Service at Poole Hospital, is a…